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CoBACKGROUND The entirely subcutaneous implantable cardioverter-deﬁbrillator (S-ICD) is the ﬁrst implantable
deﬁbrillator that avoids placing electrodes in or around the heart. Two large prospective studies (IDE [S-ICD System IDE
Clinical Investigation] and EFFORTLESS [Boston Scientiﬁc Post Market S-ICD Registry]) have reported 6-month to 1-year
data on the S-ICD.
OBJECTIVES The objective of this studywas to evaluate the safety and efﬁcacy of the S-ICD in a large diverse population.
METHODS Data from the IDE and EFFORTLESS studies were pooled. Shocks were independently adjudicated, and
complications were measured with a standardized classiﬁcation scheme. Enrollment date quartiles were used to
assess event rates over time.
RESULTS Eight hundred eighty-two patients who underwent implantation were followed for 651  345 days. Spon-
taneous ventricular tachyarrhythmia (VT)/ventricular ﬁbrillation (VF) events (n ¼ 111) were treated in 59 patients; 100
(90.1%) events were terminated with 1 shock, and 109 events (98.2%) were terminated within the 5 available shocks.
The estimated 3-year inappropriate shock rate was 13.1%. Estimated 3-year, all-cause mortality was 4.7% (95% conﬁ-
dence interval: 0.9% to 8.5%), with 26 deaths (2.9%). Device-related complications occurred in 11.1% of patients at
3 years. There were no electrode failures, and no S-ICD–related endocarditis or bacteremia occurred. Three devices
(0.3%) were replaced for right ventricular pacing. The 6-month complication rate decreased by quartile of enrollment
(Q1: 8.9%; Q4: 5.5%), and there was a trend toward a reduction in inappropriate shocks (Q1: 6.9% Q4: 4.5%).
CONCLUSIONS The S-ICD demonstrated high efﬁcacy for VT/VF. Complications and inappropriate shock rates
were reduced consistently with strategic programming and as operator experience increased. These data provide
further evidence for the safety and efﬁcacy of the S-ICD. (Boston Scientiﬁc Post Market S-ICD Registry [EFFORTLESS];
NCT01085435; S-ICD System IDE Clinical Study; NCT01064076) (J Am Coll Cardiol 2015;65:1605–15) © 2015 by the
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implantable cardioverter-
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MVT = monomorphic
ventricular tachyarrhythmia
SVA = supraventricular
arrhythmia
TV-ICD = transvenous
implantable cardioverter-
deﬁbrillator
VF = ventricular ﬁbrillation
VT = ventricular
tachyarrhythmia
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1606T he entirely subcutaneous implant-able cardioverter deﬁbrillator (S-ICD)is an alternative to transvenous im-
plantable cardioverter-deﬁbrillators (TV-ICDS)
for the prevention of sudden cardiac death
(1–4). The ﬁrst pilot phase human studies of
the S-ICD commenced in 2008, followed by
subsequent regulatory (1,2) and post-market
studies (3,4). Two studies took place to
track the initial worldwide experience with
the S-ICD (2,3). The EFFORTLESS (Boston Sci-
entiﬁc Post Market S-ICD Registry) trial (3)
began enrollment in 2009 and continues to
collect demographic, safety, and efﬁcacy
data. The IDE (S-ICD System IDE Clinical
Investigation) study began enrolling in 2009and collected the same information as the EFFORTLESS
trial. The 6-month to 1-year data for each of these trials
were reported separately, with both demonstrating
safety and efﬁcacy (2,3).SEE PAGE 1616Because of the relatively low rate of adverse events
reported in the individual trials, combining these 2
studies provided a unique opportunity to evaluate
complications and to collect a signiﬁcant number of
spontaneous events to evaluate the safety and efﬁ-
cacy of the S-ICD system over a longer follow-up
period and in a larger group of subjects. The aim of
this study is to present the world-wide experience
with the S-ICD at a mean of 22-month follow-up by
pooling these databases.
METHODS
STUDY COHORT. The study designs and endpoints
were similar, enabling this pooled analysis (Figure 1).
The pooled database consisted of 568 patients from
the EFFORTLESS registry (3), 308 from the IDE study
(2), and 13 patients from both studies, giving a total of
889 patients who underwent an implantation proce-
dure. Complications were evaluated in all patientse Medical. Dr. Gold has received consulting fees and research gran
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received November 17, 2014; revised manuscript received Februwho underwent an implantation procedure. Seven
patients underwent an implantation procedure, but
they were not discharged with a device in the IDE
study due to acute ventricular ﬁbrillation (VF) test
results, which left an implantation patient cohort of
882. Data were collected until May 21, 2013 for the
ongoing EFFORTLESS registry.
Poolability of data across studies was assessed
by analysis of incidence of complications, appro-
priate and inappropriate shocks, conversion efﬁcacy,
and mortality. In outcomes that differed by study,
exploratory analysis was performed to explain the
differences between studies.
Approval for both studies was obtained by local
ethics or institutional review boards, and informed
consent was obtained from all patients.
Device programming was determined at the dis-
cretion of the physician who performed the procedure
and was not controlled during the implantation or
study durations. The device programming features
included 2 possible tachyarrhythmia detection zones:
1) the shock only zone, in which detection and therapy
were based on rate only; and 2) an additional condi-
tional zone, in which a morphology analysis algorithm
was applied in addition to rate. Each of the zones was
described in detail in previous studies (2,3,5).
SAFETY. The complication-free rate methodology
was consistent between studies (2,3). The entire
pooled cohort was prospectively evaluated for
device-related (type I) complications, labeling-related
(type II) complications (i.e., events caused by the la-
beling, including inadequate labeling or situations
where the labeling instructions were not followed),
and procedure-related (type III) complications that
required invasive action to ameliorate the complica-
tion. The databases collected these complications over
a range of 2 to 1,542 days, including all adverse events,
but we focused on mortality, infection, inappropriate
shocks and battery longevity, capacitor function, and
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FIGURE 1 Pooled Data Population
EFFORTLESS
N = 568*
Both Studies
N = 13
IDE
N = 308
Total Pooled
N = 889
Total Implanted
N = 882
Not Implanted
N = 7
* Includes 314 enrolled prospectively and 254 enrolled retrospectively
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(A) A ﬂowchart depicts the pooled cohort of study patients broken down by each
contributing study. The designation Both Studies represents patients enrolled into both
EFFORTLESS and the IDE studies. Patients Not Implanted underwent an implant procedure
but due to high deﬁbrillation thresholds did not leave the hospital with the S-ICD. (B) The
staggered enrollment of both datasets of patients with the S-ICD. IDE enrollment began
5 months after the EFFORTLESS study enrollment, and it enrolled patients rapidly and
early in the overall cohorts timeline. The quartiles are designated Q1 when each study met
the ﬁrst 100 implants; Q2 corresponds to the approximate time the IDE study met its
enrollment goal; Q3 was the halfway mark between Q2 and the close of the EFFORTLESS
trial patient inclusion population. Quartile distribution allowed for study effect statistical
analysis between cohorts and within cohorts to place the combined data into more
accurate perspective. EFFORTLESS ¼ Boston Scientiﬁc Post Market S-ICD Registry;
FDA ¼ Food and Drug Administration; IDE ¼ S-ICD System IDE Clinical Investigation;
ICD ¼ implantable cardioverter deﬁbrillator; S-ICD ¼ entirely subcutaneous implantable
cardioverter deﬁbrillator; SVA ¼ supraventricular arrhythmia; VT ¼ ventricular tachycardia;
VF ¼ ventricular ﬁbrillation; US ¼ United States; UK ¼ United Kingdom.
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1607EVALUATION OF SPONTANEOUS EVENTS. Sponta-
neous events were deﬁned as episodes that triggered
the device to charge and store an electrogram. This
required an episode to be sustained, such that the
initial 18 and/or 24 beats of the tachycardia charge
criterion was met. For analysis, spontaneous ven-
tricular tachyarrhythmia (VT)/VF episodes (treated
and untreated) were subdivided into 2 classes:
1) discrete episodes; or 2) VT/VF storm episodes that
included 3 or more treated VT/VF episodes within
24 hours in the same patient (6). Deﬁning these
groups separately prevented the device conversion
efﬁcacy rates from being disproportionately affected
by a small number of patients who experienced
multiple, temporally clustered events.
Rhythm classiﬁcation of treated and untreated
sensed events were reported by the site, and appro-
priateness of therapy or detection was adjudicated by
a sponsor committee (EFFORTLESS) or Clinical Events
Committee (IDE). Every spontaneous stored episode
was also classiﬁed as discrete or as a storm event.
THERAPY CHARACTERISTICS. Evaluation of the
time to therapy for spontaneous episodes was deﬁned
from the onset of the sustained arrhythmia until a
shock was delivered using electrograms produced by
interrogation of the S-ICD system. Treatment out-
come was deﬁned as successful by type I termination
(abrupt) or type II (gradual termination before rede-
tection) conversion. First shock efﬁcacy was deﬁned
as conversion of VT/VF arrhythmia before the start of
a second charge. Failure to convert was deﬁned as
exhaustion of the 5 programmed therapies per event.
STATISTICAL ANALYSIS. Descriptive statistics are
reported usingmean SD, unless otherwise indicated.
Kaplan-Meier analyses were used to estimate the time
to ﬁrst event for mortality, complications, and appro-
priate and inappropriate shocks. Summary statistics
were also used to describe the overall rates for these
events and spontaneous conversion efﬁcacy. Study
effect, which was deﬁned as the difference in inci-
dence rates that were signiﬁcantly different between
the 2 study databases, was incorporated to adjust for
major differences. All statistical analyses were per-
formed using the SAS Enterprise Guide, version 4.3
(SAS 9.3, SAS Institute, Cary, North Carolina).
RESULTS
PATIENT CHARACTERISTICS. The pooled cohort
included 889 enrolled patients (detailed characteris-
tics are listed in Table 1), 882 of whom had devices
and who were followed for a mean of 651  345 days
(total patient-years: 1,571.5). The population wasgenerally younger, men, and had more preserved
ejection fractions than those previously reported in
prospective TV-ICD trials (7–9). Primary prevention
patients, patients with heart failure, coronary artery
disease, atrial ﬁbrillation, and patients with previous
TV-ICDs were well represented. The primary pre-
vention patients who had ejection fractions #35
accounted for 43% of the study population, and
TABLE 1 Baseline Demographic and Medical History
Pooled IDE and
EFFORTLESS Patients
Age, yrs 50.3  16.9 (52.6)
7.0–88.0
Sex
Men 636 (72.5)
Women 241 (27.5)
Height, cm 174.6  10.3 (175.0)
137.0–208.0
Weight, kg 86.1  22.8 (82.0)
18.0–230.9
BMI, kg/m2 28.2  6.6 (27.0)
15.2–69.0
Indication
Primary prevention 610 (69.9)
Secondary prevention 263 (30.1)
Primary cardiac disease
Ischemic cardiomyopathy 330 (37.8)
Nonischemic cardiomyopathy 277 (31.8)
Genetic 58 (6.7)
Idiopathic VF 40 (4.6)
Channelopathies 90 (10.3)
Other 77 (8.8)
Ejection fraction, % 39.4  17.6 (34.0)
10.0–86.0
Medical history
NYHA functional classiﬁcation II–IV 327 (37.5)
Atrial ﬁbrillation 143 (16.4)
COPD 56 (6.4)
Congestive heart failure 369 (42.3)
Diabetes 156 (17.9)
Creatinine clearance <45 34 (3.9)
Hypertension 331 (38.0)
Myocardial infarction 302 (34.6)
Stroke 45 (5.2)
Valve disease 114 (13.1)
Ablation 40 (4.6)
CABG 101 (11.6)
Previous deﬁbrillator 120 (13.7)
Previous pacemaker 22 (2.5)
Concomitant pacemaker at implant 19 (2.2)
Percutaneous revascularization 195 (22.3)
Value surgery 53 (6.1)
Values are mean  SD (median), range, or n (%).
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting;
COPD ¼ chronic obstructive pulmonary disease; EFFORTLESS ¼ Boston Scientiﬁc
Post Market S-ICD Registry; IDE ¼ S-ICD System IDE Clinical Investigation;
NYHA ¼ New York Heart Association; VF ¼ ventricular ﬁbrillation.
TABLE 2 Summary of Initial Programming
Statistic/Category Pooled IDE and EFFORTLESS Patients
Lowest rate zone 197.5  19.2 (200.0)
90.0–250.0
Zones
Dual zone 689 (79.2)
Single zone 170 (19.5)
Missing 10 (1.1)
Off 1 (0.1)
Vector
Primary 452 (52.6)
Secondary 313 (36.4)
Alternate 94 (10.9)
Values are mean  SD (median), range, n (%).
Abbreviations as in Table 1.
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1608together with secondary prevention patients (n ¼ 263;
mean ejection fraction: 30%), made up most of the
patients who underwent implantation. Chronic kid-
ney disease patients were enrolled. Only EFFORT-
LESS included patients with end-stage renal disease
because the IDE study excluded them.
The majority of S-ICD patients enrolled with pre-
vious TV-ICDs presented with infection that required
TV-ICD extraction (63%), with the remainder mostlyexperiencing failed or malfunctioned TV-ICD leads
that were either removed or abandoned. Patients with
a previous bipolar pacemaker were included (n ¼ 19).
These patients were screened by protocol and un-
derwent acute conversion testing at maximum output
and asynchronous mode pacing. No patients were
implanted with a bradycardia device simultaneously.
Patients who had an S-ICD replaced with a TV-ICD
are described in the following text.
Patients who received devices for secondary pre-
vention were in the minority (n ¼ 263). The majority
of these patients had VF or polymorphic VT as the
index arrhythmia (75%), although patients with a
higher VT (>170 beats/min) were included. Secondary
indication patients with tachycardias that were reli-
ably terminated with antitachycardia pacing (ATP)
were excluded.
A summary of the initial S-ICD device program-
ming is provided in Table 2. The majority of devices
were programmed with 2 zones, which provided
morphologic discrimination of events with rates in
the conditional shock zone. Detection cutoff rates
for VF were chosen at the discretion of the operator,
and the median of the lowest rate zone was 200
beats/min.
There were no differences in the incidence of
appropriate shocks, conversion efﬁcacy, or mortality
by study. However, a study effect was noted for a
higher rate of inappropriate shocks and complications
in the IDE study (early regulatory implantations)
compared with the EFFORTLESS trial (post-regulatory
commercial implantations).
FREEDOM FROM COMPLICATIONS. The number and
type of complications throughout the follow-up
period are listed in Table 3 and are illustrated in the
Kaplan-Meier curve in the Central Illustration; 4.5% of
patients experienced a complication within 30 days
TABLE 3 All Type I to III Complications
Description
Complications
Events Patients
Infection requiring device removal/revision 17 14 (1.7)
Erosion 12 11 (1.2)
Discomfort 8 8 (0.9)
Inappropriate shock: oversensing 8 8 (0.9)
Suboptimal electrode position 7 7 (0.8)
Electrode movement 7 5 (0.6)
Inappropriate shock: SVA above discrimination
zone (normal device function)
6 6 (0.7)
Premature battery depletion 5 5 (0.6)
Hematoma 4 4 (0.4)
Suboptimal PG and electrode position 4 4 (0.4)
Adverse reaction to medication 3 3 (0.3)
Inability to communicate with the device 3 3 (0.3)
Inadequate/prolonged healing of incision site 3 3 (0.3)
Incision/superﬁcial infection 3 3 (0.3)
Suboptimal PG position 2 2 (0.2)
Other procedural complications 11 8 (0.9)
Other technical complications 5 5 (0.6)
Total 108 85 (9.6)
Values are n (%).
PG ¼ pulse generator; SVA ¼ supraventricular arrhythmia.
J A C C V O L . 6 5 , N O . 1 6 , 2 0 1 5 Burke et al.
A P R I L 2 8 , 2 0 1 5 : 1 6 0 5 – 1 5 2-Year Safety and Efﬁcacy of the S-ICD
1609and 11.1% of patients had a complication over 3 years.
The 3-year Kaplan-Meier estimate for patients with a
type I complication was 5.4%.
Of 108 total complications, 43 (40%) occurred in
the ﬁrst 30 days. Of 85 patients with complications,
14 patients had 2 or more complications (1.57% of 889
patients who underwent an implantation procedure),
and 71 patients had 1 complication (7.99% of pa-
tients). Of the 14 patients with more than 1 compli-
cation, pocket erosion (n ¼ 7) was most often
associated with other adverse events. One patient
had the same complication (electrode movement)
twice, with no other complications. Infection and
suboptimal pulse generator or electrode position
were the most common complications. Suboptimal
position of the electrode or pulse generator was
resolved by revisions of the electrode or pulse
generator; 5 of 13 events occurred during the im-
plantation procedure, and an additional 5 events
occurred within 7 days after implantation. Five de-
vice malfunctions, such as early battery depletion
(0.6%) and inability to communicate with the pro-
grammer (0.3%), were very rarely seen. There were no
electrode failures throughout the follow-up period or
any S-ICD–related bacteremia.
Extraction of the S-ICD for pacing occurred in 4
patients (0.4%) due to the need for ventricular
pacing: 1 patient developed a new bradycardia indi-
cation; 1 patient was explanted because of need forATP; and 1 patient with 3 VT storm events underwent
replacement with a TV-ICD in an attempt to suppress
ventricular arrhythmias using overdrive pacing. In
addition, 1 device was extracted for a cardiac
resynchronization therapy upgrade.
A study effect was observed for complications (p ¼
0.0857). When correcting for the time of enrollment,
the effect of the study was not signiﬁcant (p ¼
0.5924), which indicated that time rather than the
study explained the difference in complication rates
between the studies. This result is further illustrated
in Figure 2A.
EFFICACY. The Kaplan-Meier incidence of time to
ﬁrst therapy for VT/VF was 5.3% at 1 year, 7.9% at 2
years, and 10.5% at 3 years. Excluding VT/VF storms,
111 discrete VT/VF events were treated, with 100
(90.1%) terminated with the ﬁrst shock, and 109
(98.2%) terminated within the 5 shocks available. Of
51 PVT/VF episodes in 32 patients, 45 (88.2%) were
converted with a single shock. Sixty monomorphic
VT (MVT) episodes were recorded in 40 patients,
and 55 (91.7%) were converted on the ﬁrst shock. All
MVT episodes were converted within the 5 shocks
available. Of 2 unconverted polymorphic VT/VF epi-
sodes, 1 spontaneously terminated after the ﬁfth
shock, but beyond the time frame of the electro-
graphic recording. In the other episode, the device
prematurely declared the episode ended due to un-
dersensing after 2 shocks. A new episode was imme-
diately re-initiated, and the VF was successfully
terminated with 1 additional shock.
There were 12 VT/VF storms observed in 7 pa-
tients. Storm events were converted in 10 of 12
events. One of the other 2 patients received multiple
S-ICD shocks for VT and was brought by ambulance
to the hospital, during which time external deﬁbril-
lation was also applied. Each S-ICD and external
deﬁbrillation shock resulted in conversion of the VT,
followed shortly by re-initiation, until the VT was
ultimately terminated by an external deﬁbrillator
shock. There was 1 previously reported patient
with rare Loefﬂer’s syndrome who experienced failed
conversion of a terminal VF event subsequent to a
10-min bradycardia episode (3). This patient under-
went S-ICD implantation after obliteration of the
right and left ventricular apexes by a mass
and was not deemed suitable for a standard ICD
system (3).
A total of 104 (11.8%) patients had 314 episodes of
VT/VF detected during the follow-up period where
both untreated and appropriately treated VT/VF ep-
isodes in discrete and storm events were evaluated.
There were 115 appropriately detected VT/VF
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(Top) This survival curve represents the 3-year complication-free rate for type I to III complications that require invasive action to correct.
The majority of complications occurred in the ﬁrst 30 days from implantation. (Bottom) This survival curve represents a comparison of the
3-year inappropriate shock-free rate by programmed zone. The single zone describes a shock-only zone, whereas the dual zone indicates
2 separate cutoff rates, with the lower cutoff rate including a morphology discrimination algorithm to help distinguish supraventricular
arrhythmia (SVA) from ventricular arrhythmia. Dual zone programming is the preferred permanent programming due to the signiﬁcantly lower
inappropriate shock rate for SVA and oversensing. K-M ¼ Kaplan-Meier.
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FIGURE 2 Events by Patient Enrollment Order and Programming
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(A) The 6-month incidence of complications and infections that required device removal by enrollment date. More experience with the device implant and management
led to a decreased trend in overall complication and infection rates over time (Figure 1B). (B) The incidence of shocks (appropriate and inappropriate) by quartiles as
previously described. The primary or y- axis shows the percent of patients who received an appropriate or inappropriate shock in the ﬁrst 6 months, for those patients
who underwent implantation at least 6 months previously (this only included patients with the opportunity to complete 6 months of follow-up). The decrease in single-
zone programming shows a decrease in inappropriate shock without alterations in the incidences of appropriate shock. Other inﬂuential clinical features leading to this
ﬁnding include physician experience with implantation.
J A C C V O L . 6 5 , N O . 1 6 , 2 0 1 5 Burke et al.
A P R I L 2 8 , 2 0 1 5 : 1 6 0 5 – 1 5 2-Year Safety and Efﬁcacy of the S-ICD
1611episodes that self-terminated before shock delivery;
70% of these were MVTs (76 MVTs in 58 patients,
35 VFs/polymorphic VTs in 12 patients, and 4 were
ventricular without site reported rhythm adjudica-
tion) compared with 199 appropriately detected
episodes that were sustained long enough to require
an 80-J shock. Speciﬁcally, 36 (4.1%) patients expe-
rienced events only long enough to require a shock,
whereas 41 (4.6%) patients had only untreated
or self-limiting VT/VF episodes. Finally, 27 (3.1%)
patients had both nonsustained (self-limited) and
sustained treated VT/VF episodes during the follow-
up period. During the follow-up period, 1 patient’s
MVT burden led to the clinical decision to transition
to a device with ATP capability.
The time to therapy for spontaneous episodes was
19.2  5.3 s for all VT/VF therapies (MVT 18.2  4.9 s;
polymorphic VT and VF 20.5  5.6 s). Fifteen events of
syncope in 15 different patients (1.7%) were reported.
Two patients with recorded untreated episodes were
associated with reported syncope on the day of the
episode. One event of syncope was associated with a
treated episode, in which therapy was delivered for VF
and required 5 shocks to convert. As mentioned pre-
viously, 1 episode of temporary undersensing was
noted, but eventually cycled to terminate with a
shock. All-cause mortality was 2.9% (n ¼ 26) during
the follow-up period, with only 1 known arrhythmicdeath (0.1%) due to Loefﬂer’s syndrome, as described
previously. The 2-year Kaplan-Meier mortality esti-
mate was 3.2% (95% conﬁdence interval: 1.3% to 5%),
and the 3-year Kaplan-Meier estimate was 4.7% (95%
conﬁdence interval: 0.9% to 8.5%).
INAPPROPRIATE THERAPY. The Kaplan-Meier inci-
dence of time to ﬁrst inappropriate shock was 13.1% at
3 years. In patients with dual zone programming at
the index procedure, the Kaplan-Meier incidence of
inappropriate shock at 3 years was 11.7% compared
with 20.5% with single-zone programming (Central
Illustration). The majority of patients who received
an inappropriate shock with either single or dual zone
programming received the shock in the ﬁrst year post-
implantation. The causes of inappropriate shocks
were supraventricular arrhythmia (SVA) above the
discrimination zone in 24%, SVA discrimination er-
rors in 1%, T-wave oversensing in 39%, low amplitude
signal in 21%, noncardiac oversensing (e.g., electro-
magnetic interference) in 8%, oversensing of VT/VF
below the rate zone in 4%, other and/or combined
types of cardiac oversensing in 2%, and committed
shock for VT/VF in 1%.
A signiﬁcant study effect was observed for inap-
propriate shocks (p ¼ 0.0209) revealing less contri-
bution of inappropriate shocks from the EFFORTLESS
study group. When correcting for the initial pro-
grammed number of zones, shock zone rate, and
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not signiﬁcant (p ¼ 0.1496).
RESULTS BY PATIENT ENROLLMENT DATE. The rate
of therapy for VT/VF was similar across quartiles of
enrollment in the studies (3.5% to 3.0%; p ¼ 0.41)
(Figure 2). The most recently implanted quartile of
patients had a lower rate of inappropriate shocks at
6 months, although the trend did not reach statistical
signiﬁcance (Q1: 6.9%, Q2: 6.0%, Q3: 6.5%, Q4: 4.5%,
p¼0.18), whereas therewas amajor increase in the use
of dual zone programming from 51% to 95% (p < 0.01)
(Figure 2B). The rate of infections requiring system
explantation decreased over time (p¼ 0.08), as did the
overall rate of complications (p ¼ 0.05) (Figure 2).
DISCUSSION
This paper presents the largest, most comprehensive,
and longest follow-up of efﬁcacy in the treatment of
spontaneous VT/VF episodes by the S-ICD to date.
The main ﬁndings of the pooled cohort conﬁrm that
the favorable outcomes achieved with the S-ICD
continue up to 3 years post-implantation. In addition,
the rates of inappropriate shocks, infection, and
overall complications improved in the most recently
patients who underwent implantation.
MORTALITY. The low mortality rate in this pooled
data set deserves consideration. The S-ICD annual
mortality rate of 1.6% and 2-year mortality rate of
3.2% in the pooled data compares favorably with
recent ICD trials. With controlled programming, the
MADIT-RIT (Multicenter Automatic Deﬁbrillator Im-
plantation Trial-Reduce Inappropriate Therapy) pri-
mary prevention trial had 2-year mortality rates of 5%
and 7% in the high rate and delayed therapy groups,
respectively (10). To date, S-ICD clinical trials have
not been designed or powered to assess mortality,
and care should be taken in these comparisons due to
the more heterogeneous population and high cutoff
detection rates in the S-ICD studies. MADIT-RIT also
had high-rate therapy (>200 beats/min) that was
associated with a signiﬁcant reduction in mortality
(hazard ratio: 0.45; p ¼ 0.01) and delayed therapies
that were associated with a trend toward reduced
mortality (hazard ratio: 0.56, p ¼ 0.06) compared with
conventional programming. Conversely, the pooled
data S-ICD population should have had a high risk of
sudden death because this population was composed
of a high percent of patients who had indica-
tions for secondary prevention (32%). Similarly, the
SIMPLE (Shockless IMPLant Evaluation Trial) trial
included nearly 30% of patients who required sec-
ondary prevention among 2,500 patients, but it found
a higher 2-year mortality rate of 11% (11). To be fair,the S-ICD experience had younger patients (mean age
50 years) with higher ejection fractions (mean 0.39);
therefore, these patients had less advanced heart
failure and more functional reserve, which might be
factors that explain the lower annual mortality rate.
This was a provocative ﬁnding that was not pro-
spectively powered in either study. However, it is an
important aspect that deserves detailed scrutiny and
longer term analysis with matched ICD populations
without a pacing indication to understand a possible
nontransvenous phenomenon.
INFECTION AND COMPLICATIONS. A population-
based improvement in mortality with a new device
is paramount, but can be negated if the implant
carries a higher risk of removal due to pocket infec-
tion. Infection, without any bacteremia, remained the
most common complication that required invasive
action in the early experience with the S-ICD (2–4).
This was also true in the pooled analysis presented in
this paper. Many steps were taken to mitigate this
risk, including better operative preparation training
and techniques, and aggressive management of skin
infections to prevent device removal (3). Advances in
implantation techniques were introduced into the
literature by Knops et al. (12) in an effort to decrease
the incisional surface area and reduce infection risk.
Advances in operator experience, preparation, and
implantation technique appeared to have positively
affected the rates of infection as use of the S-ICD
system has expanded worldwide. The simplicity of
implantation that avoided vascular access was re-
ﬂected in the very low (2%) rate of acute major com-
plications (hematoma, lead/device malpositioning/
displacement) seen post-operatively versus the in-
hospital major adverse events of 1.9% for single-
chamber and 2.9% for dual-chamber ICDs in the
National Cardiovascular Database Registry ICD Reg-
istry, respectively, including lead displacement (0.5%
and 0.9%, respectively), hematoma (0.6% and 0.8%,
respectively), and pneumothorax (0.3% and 0.5%,
respectively) (13). The rate of major complications
rose to 3.5% for single-chamber ICDs and 4.8% for
dual-chamber ICDs through the ﬁrst 90 days of
follow-up when the National Cardiovascular Database
Registry database was linked to Medicare (14). Even
higher rates of TV-ICD hematomas (2.2%) and lead
displacement (1.8%) were reported for ICD patients
in a pooled meta-analysis of randomized controlled
trials (15).
APPROPRIATE TREATMENT EFFICACY. The success
of the S-ICD system in detecting and deﬁbrillating
spontaneous VT/VF events presented in this paper
validates the treatment efﬁcacy of the system. The
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venous spontaneous event conversion, with 90%
success at ﬁrst shock efﬁcacy and >98% efﬁcacy
overall (15–17). First shock efﬁcacy for spontaneous
events in TV-ICDs was 83% in the SCD-HeFT (Sudden
Cardiac Death in Heart Failure Trial) (16), 89% in
LESS (Low Energy Safety Study) (17), and 90%
in ALTITUDE (Long term outcome after ICD and
CRT implantation and inﬂuence of remote device
follow up study) (18). In the MADIT-CRT (Multicenter
Automatic Deﬁbrillator Implantation Trial-Cardiac
Resynchronization Therapy) trial, which had a more
morbid population, ﬁrst shock efﬁcacy for conversion
of spontaneous VT/VF was not different by dual coil
(89.6%) or single coil (92.3%) leads (19), and conver-
sion efﬁcacy over all shocks was 97.3% to 99.6%
(17,18). Earlier reports of S-ICD efﬁcacy relied on
acute and long-term–induced conversion testing to
prove shock efﬁcacy, but there was a paucity of
spontaneous events to corroborate (1–3). In combi-
nation, the spontaneous event conversion efﬁcacy
and mortality data in this paper are the most impor-
tant additions to the S-ICD evidence base of experi-
ence under real-life circumstances to date.
A major cause for concern against implanting the
S-ICD is the possibility that patients indicated for
deﬁbrillator therapy will beneﬁt from ATP. Patients
with recurrent VT reliably terminated with ATP were
excluded from both the IDE and EFFORTLESS studies
(2,3). The frequency and type of such events reported
in this paper suggests that the investigators selected
patients appropriately; only 1 patient had the S-ICD
replaced with a TV-ICD to provide ATP. In this cohort
of S-ICD patients, there were 13 patients (1.4%) with
more than 1 MVT episode treated, including 2 patients
with storm events. This rendered an annualized rate
of recurrent treated MVT of 0.8%. In a subanalysis
of SCD-HeFT patients, Poole et al. (20) reported that
7% of 811 patients experienced more than 1 VT
episode during the 46-month follow-up, rendering
a 1.8% annual beneﬁt for ATP. The PainfreeRx II
(Pacing Fast Ventricular Tachycardia Reduces Shock
Therapies) trial (21), which targeted patients with
substrates for stable MVT, demonstrated a 42%
reduction in shock episodes for fast VT using ATP
versus shocks alone (57 vs. 99 episodes). Considering
the rate of recurrent MVT in this cohort, it could be
hypothesized that there was an estimated 0.3%
annual beneﬁt from ATP, or approximately 1%, if
patients with any MVT were included. Due to the
rapid time to therapy used at the time of SCD-HeFT
and PainfreeRx II, these might be overestimates of
required therapy. The MADIT-RIT study (10) showed
that 22% of patients in the conventional programmingarm received appropriate ATP, compared with 8%
and 4% in the high rate and delayed therapy arms,
respectively. Despite a difference in the rate of
appropriate ATP therapy, there was no difference
in patients who received appropriate shocks
(5% with conventional programming or high rate
programming, and 4% with delayed therapy over 1.4
years). This is comparable to our data, in which
appropriate shock incidence was 5.3% over 1 year.
The decrease in the appropriate episodes as implan-
tation experience and dual zone programming
increased at higher cutoff rates similar to the MADIT-
RIT trial (10) are of particular interest. The S-ICD pa-
tient selection, exclusion criteria, and actual event
analysis suggest a limited beneﬁt to ATP therapy in
the patient cohort presented here.
Nontreatment of self-terminating, prolonged epi-
sodes of VT/VF are as important as successfully con-
verted VT/VF episodes. The 125 episodes of VT/VF
that self-terminated without associated reports of
syncope or mortality conﬁrm the appropriateness of
a more deliberate time-delayed strategy in tachyar-
rhythmia sensing algorithms, such as the S-ICD
algorithm, to avoid unnecessary shocks.
INAPPROPRIATE SHOCK RATE. The incidence of
inappropriate shocks in this pooled cohort was higher
than the EFFORTLESS patients alone, and was
driven by the early experience of the IDE study. Pre-
implantation screening methods and experience have
evolved (22). Publication of the START (Head to head
comparison of arrhythmia discrimination performance
between subcutaneous and transvenous arrhythmia
detection algorithm trial) Study and MADIT-RIT led to
higher cutoff rates and dual zone programming, with
signiﬁcant reductions in inappropriate shocks (10,23).
In this pooled analysis, dual zone programming
increased from 51% to 95% and was driven by lessons
learned from the START study and early implantations
in the IDE and EFFORTLESS studies. The 6-month
incidence of inappropriate shocks dropped by 34%
from the ﬁrst quartile of enrolled patients to the last
quartile of enrolled patients.
The S-ICD has so far been implanted for a wide
variety of indications, including many patients at
high risk of deﬁbrillation failure (hypertrophic car-
diomyopathy patients, renal failure patients, and
patients with post–TV-ICD infection) and in younger
patients with primary electrical or structural con-
genital disease. The context of the appropriate and
inappropriate therapies in patients with the S-ICD
needs to include consideration of these broad sub-
strates and circumstances as the use of the S-ICD
system expands in such groups.
PERSPECTIVES
COMPETENCY IN PATIENT CARE: Automatic
S-ICDs without transvenous high voltage electrodes
are effective in detecting and terminating VTs and
avoiding mortality in patients at high risk of sudden
death; they are also associated with relatively low
rates of lead failure or complications that require
repeated operations. Over 3 years of follow-up, the
most frequent adverse events were generator pocket
infection and inappropriate shocks resulting from
oversensing.
TRANSLATIONAL OUTLOOK: Further engineering
enhancements and advances in dual zone program-
ming at higher cutoff rates should be directed at
decreasing inappropriate shocks.
Burke et al. J A C C V O L . 6 5 , N O . 1 6 , 2 0 1 5
2-Year Safety and Efﬁcacy of the S-ICD A P R I L 2 8 , 2 0 1 5 : 1 6 0 5 – 1 5
1614STUDY LIMITATIONS. This pooled analysis combined
data from 2 separate databases with predominately
prospectively enrolled patients. Combining the
groups introduced a risk of bias as did the inclusion
of some retrospectively enrolled patients into the
pool for analysis. However, the groups were pooled
because of the congruent nature of the inclusion
and/or exclusion criteria of the studies, as well as the
timing of their enrollment. The collection of data and
analysis of complications was also consistent be-
tween the studies. Mortality comparisons to other
studies are difﬁcult due to demographic differences
and lack of data on patients withdrawn from
the study. EFFORTLESS allowed enrollment post-
implantation, a factor that might introduce a sur-
vival bias in these patients.
CONCLUSIONS
The S-ICD showed very high shock efﬁcacy for spon-
taneous ventricular arrhythmias and a decreasing
incidence of inappropriate shocks. The complication-
free rate and low mortality rate extended beyond the
ﬁrst year. The rate of inappropriate shocks and the
risks of infection and total complications decreased as
physicians who performed the procedure gained more
experience with the device. These data provided
further support for the safety and efﬁcacy of the S-ICD
in patients with primary and secondary indications
without pacing indications over a 3-year period.
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